Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
百明信康生物技术（杭州）有限公司 Worgpharma logo — Innovative solutions for allergy and autoimmune diseases thr...

百明信康生物技术（杭州）有限公司 Worgpharma

Innovative solutions for allergy and autoimmune diseases through advanced technology platforms and strategic collaborations.

Founded 2018 19 employees Series C Total: $1.70B Biotechnology

General Information

Company Name 百明信康生物技术（杭州）有限公司 Worgpharma
Founded Year 2018
Employees 19
Industries Biotechnology
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with 百明信康生物技术（杭州）有限公司 Worgpharma. To contact 百明信康生物技术（杭州）有限公司 Worgpharma, visit worgpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 百明信康生物技术（杭州）有限公司 Worgpharma compare?

A PDF of 百明信康生物技术（杭州）有限公司 Worgpharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 百明信康生物技术（杭州）有限公司 Worgpharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 百明信康生物技术（杭州）有限公司 Worgpharma

**Worgpharma** is a **biotechnology** startup founded in **2018** with a focus on innovative solutions for allergy and autoimmune diseases. The company's slogan, "Innovative solutions for allergy and autoimmune diseases through advanced technology platforms and strategic collaborations," reflects its commitment to leveraging advanced technology platforms and strategic partnerships to address unmet medical needs. Worg is advancing a lineup for allergy and autoimmune conditions using two primary technology platforms, **PCFiT** and **Apitope**, through both internal research and collaborations with adaptable business models. Moreover, Worg is developing a platform for **molecular allergy diagnosis**. Notably, **Worgpharma** recently secured a significant **CNY1.10B Series C investment** on **29 June 2023**. The investment was made by a consortium of investors including **DT Capital Partners**, **Kangjun Capital**, **Shanghai Bairun Investment Holding Group**, **Kequan Fund**, **Shanghai Qinda Investment Holding Group**, and **Jiansu Ziben**. This substantial investment underscores confidence in Worg's innovative approaches and potential to make a meaningful impact in the biopharmaceutical space.

Business keywords: biopharmaceutical, allergy treatment, autoimmune diseases, clinical-stage, technology platforms, PCFiT, Apitope, molecular diagnosis, strategic collaborations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C CNY1.10B 6
DT Capital Partners
DT Capital Partners, Kangjun Capital +4
29 Jun 2023
Series B CNY400.00M 4
Kaitai Capital Puhua Capital
Kaitai Capital, Puhua Capital +2
14 Sep 2022
Series A CNY200.00M -
18 Jan 2021

百明信康生物技术（杭州）有限公司 Worgpharma Alternatives & Competitors

View All Alternatives
百明信康生物技术（杭州）有限公司 Worgpharma vs
ZaBeCor Pharmaceuticals
ZaBeCor Pharmaceuticals

Pioneering molecular advancements for asthma, allergies, and a spectrum of inflammatory and infectio...

Venture round
2 employees
Biotechnology, Health Care
百明信康生物技术（杭州）有限公司 Worgpharma vs
VentiRx Pharmaceuticals
VentiRx Pharmaceuticals

Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune dis...

Series B
Biotechnology, Health Care
百明信康生物技术（杭州）有限公司 Worgpharma vs
DBV Technologies
DBV Technologies France

On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin...

Post-IPO Equity
187 employees
Biopharma, Biotechnology
View all alternatives

FAQ About 百明信康生物技术（杭州）有限公司 Worgpharma

Innovative solutions for allergy and autoimmune diseases through advanced technology platforms and strategic collaborations.
百明信康生物技术（杭州）有限公司 Worgpharma was founded in 2018.
百明信康生物技术（杭州）有限公司 Worgpharma operates in Biotechnology. Its work centres on biopharmaceutical, allergy treatment, autoimmune diseases and clinical-stage.
百明信康生物技术（杭州）有限公司 Worgpharma has approximately 19 employees.
百明信康生物技术（杭州）有限公司 Worgpharma has completed 3 funding rounds, raising a total of $1.70B. The latest funding stage is Series C.
Top alternatives and competitors to 百明信康生物技术（杭州）有限公司 Worgpharma include ZaBeCor Pharmaceuticals, VentiRx Pharmaceuticals, DBV Technologies, Reistone Biopharma, Alder Biopharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
百明信康生物技术（杭州）有限公司 Worgpharma and ZaBeCor Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 百明信康生物技术（杭州）有限公司 Worgpharma, https://bouncewatch.com/company/worgpharma, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes